Skip to main content

Tag: Highlighted

Dr. Lora Giangregorio Named Canada Research Chair

Close up of a hand using a tablet

Latest News

Dr. Lora Giangregorio Named Canada Research Chair

March 19, 2025

Dr. Lora Giangregorio

Lora Giangregorio, PhD

The University of Waterloo, Kinesiology and Health Sciences Professor Lora Giangregorio has been awarded a Tier 1 Canada Research Chair (CRC) in Bone Health and Exercise Science, with a funding allotment of $1.4 million.

The Tier 1 Canada Research Chair will advance bone health and exercise science research.

Dr. Giangregorio also received a $75,000 grant from the Canada Foundation for Innovation John R. Evans Leaders Fund (JELF) that is associated with this CRC.

Dr. Giangregorio is a member of Osteoporosis Canada’s Scientific Advisory Council (SAC). Her research team has also worked with the organization to develop Bone Fit™, a two-day workshop for physiotherapists and kinesiologists on exercise prescription for those with osteoporosis.

Dr. Giangregorio is recognized for her outstanding research in reducing the burdens of osteoporotic (bone tissue) fractures. She leads the University of Waterloo Bone Health and Exercise Science Lab (BonES), working on exercise research to reduce fracture risk.

Congratulations to Dr. Giangregorio!

Click here to visit the University of Waterloo and read the full announcement.

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario

Close up of a hand using a tablet

Latest News

Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario

February 20, 2025

Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.

Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.

To view more information about provincial and territorial drug coverage visit https://osteoporosis.ca/provincial-territorial-drug-coverage/

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

2024 Gideon A. Rodan Excellence in Mentorship Award

Close up of a hand using a tablet

Latest News

2024 Gideon A. Rodan Excellence in Mentorship Award

Angela Cheung, M.D., Ph.D. is the recipient of the 2024 Gideon A. Rodan Excellence in Mentorship Award which is given annually in recognition of outstanding support provided by a senior scientist who has helped promote the independent careers of young investigators in bone and mineral metabolism.

The ASBMR Esteemed Awards are the Society’s most prestigious awards given to members who have made significant contributions and who promote excellence in bone and mineral research.

Angela Cheung, M.D., Ph.D.  2024 Gideon A. Rodan Excellence in Mentorship Award Recipient

Dr. Angela M. Cheung is Professor of Medicine at University of Toronto, Senior Physician Scientist at University Health Network, and holds a Tier 1 Canada Research Chair in Postmenopausal and Musculoskeletal Health. She obtained her M.D. from Johns Hopkins University in 1988 and her Ph.D. in Health Policy from Harvard University in 1997. She is a Fellow of the Royal College of Physicians of Canada and has been in clinical practice for more than 30 years. Dr. Cheung is also a member of Osteoporosis Canada’s Scientific Advisory Council, a member of the IOF Council of Scientific Advisors and the President-Elect of ISCD.

This award will be presented during the ASBMR 2024 Annual Meeting in Toronto this September.

Congratulations to Dr. Angela Cheung!

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis.

Close up of a hand using a tablet

Latest News

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis.

May 31, 2024

Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, reference medicine: Prolia).

Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass. This human monoclonal antibody and RANK ligand inhibitor (bone metabolism regulator) is approved to treat all five indications covered by the reference medicine and is available as a 60 mg/mL solution in single-use prefilled syringe. Jubbonti® should be available on the Canadian market in the coming months.

“This announcement means that Canadians will have greater access to an important biologic therapy in the treatment of osteoporosis,” says Dr. Famida Jiwa, President and CEO, Osteoporosis Canada. “Health Canada’s approval of the denosumab biosimilar Jubbonti®will expand and increase access to patients who are living with osteoporosis.”

Click here to visit Sandoz and read the full release.

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

Dr. Angela Man-Wei Cheung ISCD 2024 Board Announcement

Close up of a hand using a tablet

Latest News

Dr. Angela Man-Wei Cheung ISCD 2024 Board Announcement

April  19, 2024

Dr. Angela Man-Wei Cheung, MD, PhD, FRCPC, CCD
Angela Man-Wei Cheung, MD, PhD, FRCPC, CCD

The International Society for Clinical Densitometry (ISCD) is the leading membership organization for professionals working to assess, monitor and treat skeletal health.

Dr. Angela Man-Wei Cheung, from University Health Network, the University of Toronto and member of Osteoporosis Canada’s Scientific Advisory Council (SAC), has recently been named the ISCD President-Elect.

Dr. Cheung served as Vice President in 2023-2024. 

ISCD is committed to improving the quality of diagnosis, treatment and care provided to patients by promoting excellence in the field of bone densitometry. ISCD provides continuing education and certification to physicians and technologists in the medical community that have an interest in the field of bone densitometry. 

ISCD is impacting quality densitometry and osteoporosis treatment in over 25 countries, from Australia to Uruguay — connecting researchers, technologists, physicians, and others with an interest in the field as well as partnering with other organizations to deliver the most impactful information to its members.

The ISCD Board of Director members are leaders in the field of densitometry and osteoporosis—top practitioners, technologists and researchers who serve to help grow and lead the industry. 

Congratulations Dr. Cheung!

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture

Close up of a hand using a tablet

Latest News

Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture

April 3, 2024

Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.

EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.

Click here to visit AMGEN Canada and read the full release

To learn more about osteoporosis treatments visit https://osteoporosis.ca/treatments/

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

IOF Welcomes Dr. Famida Jiwa as Chair of the Committee of National Societies

Close up of a hand using a tablet

Latest News

IOF Welcomes Dr. Famida Jiwa as Chair of the Committee of National Societies

February 9, 2024

Following the elections held for the position of Chair of the International Osteoporosis Foundation (IOF) Committee of National Societies (CNS), Dr. Famida Jiwa, President and CEO, Osteoporosis Canada has been elected Chair for the term 2024-2028.

As Chair of the IOF CNS, Dr. Jiwa will be sitting on the Board of Trustees as an ex-officio member and her term as Chair of the CNS will formally start in April 2024, on the occasion of the Committee of National Societies Annual Meeting, planned in London on April 11, 2024.

Dr. Jiwa will have the opportunity to designate the Vice-Chair of the CNS, who will be introduced to all CNS Members during the CNS Annual Meeting in London.

Congratulations to Dr. Famida Jiwa.

IOF Logo

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

CIHR Institute of Aging Award Winners for 2022-2023

Close up of a hand using a tablet

Latest News

CIHR Institute of Aging Award Winners for 2022-2023

November 7, 2023

Congratulations to Dr. Alexandra Papaioannou, member of the Osteoporosis Canada Scientific Advisory Council (SAC) is one of the recipients of The 2023 CIHR Institute of Aging Betty Havens Prize for Knowledge Mobilization in Aging.

The CIHR Institute of Aging Betty Havens Prize for Knowledge Mobilization in Aging honors Betty Havens, a leading gerontologist who was committed to improving the lives of seniors with notable achievements in health services research on the aging process. This prize, based on nominations of applicants by peers, teams or organizations, recognizes an individual, team or organization that has advanced the mobilization of research in aging at a local or regional level.

Dr. Alexandra Papaioannou is a Professor of Medicine (Division of Geriatrics) at McMaster University, a Geriatric Medicine Specialist at Hamilton Health Sciences and Executive Director of the Geras Centre for Aging Research. She holds a Tier 1 Canada Research Chair in Geriatric Medicine and Healthy Aging. She is the lead clinician-scientist of the Canadian Geriatrics Society Frailty working group and a member of the Global Frailty Network.

Dr. Papaioannou is the Chair of the Regional Geriatric Program Central and past Director of the Division of Geriatric Medicine at McMaster University. She has 396+ peer-reviewed publications, 19 book chapters and 417+ published abstracts (h-index 76; 24,629+ citations). She has mentored 125+ research trainees from undergraduate to post-doctoral fellows, many of whom have received nationally-funded awards. Her program of research is focused on bringing the best research evidence to the frontlines of care for older adults to age with dignity and independence.

Congratulations to Dr. Papaioannou.

LATEST NEWS


OC MAKES THE NEWS – RECENT ITEMS

Highlighted

Continue reading

A New Clinical Practice Guideline for management of osteoporosis and fracture prevention in Canada

Close up of a hand using a tablet

Latest News

A New Clinical Practice Guideline for management of osteoporosis and fracture prevention in Canada

October 10, 2023

On October 10, 2023, a new guideline on managing osteoporosis to assist Canadian healthcare providers has been published by the Osteoporosis Canada 2023 Guideline Update Group in the Canadian Medical Association Journal (CMAJ).

With over 2.3 million Canadians living with osteoporosis, this guideline is intended to assist Canadian primary care providers in the delivery of care to optimize skeletal health and prevent fractures in postmenopausal females and in males 50 years and older.

“We are hopeful that this Canadian guideline will empower healthcare professionals and patients to have meaningful discussion on the importance of skeletal health and fracture prevention to preserve mobility and autonomy across adulthood.” says Dr. Suzanne Morin, lead author and Chair of the 2023 guideline steering committee.

Advancements in risk assessment and disease management warranted an update to the Osteoporosis Canada 2010 clinical practice guidelines. The 2023 guideline contains 25 recommendations and 10 good practice statements with a focus on exercise, nutrition, fracture risk assessment, treatment and more – reflecting advances in risk assessment, and nonpharmacologic and pharmacologic management of osteoporosis.

The guideline is based on the latest evidence and included patient partners in developing the recommendations.

“I am pleased that the new guideline addresses concerns so often raised by patients including issues on treatment initiation, drug holidays and falls prevention” says Larry Funnell, patient advocate. “Our voices have been heard. Patient contributions to the new guideline have been significant, whether as full partners engaged in all the expert working groups, or as one of the more than 1,000 Canadians who responded to the survey seeking patient input to the development of the guideline.”

As the Canadian population ages, it is important, now more than ever, for healthcare providers to implement the guideline into everyday practice to ensure Canadians living with osteoporosis receive the highest quality care.  The guideline will help care providers develop individualized and strategic care plans suited to their particular needs.

“The release of the Osteoporosis Canada 2023 Clinical Practice Guideline will support Canadian healthcare providers in providing the most current evidence-based information for patient centred care to optimise skeletal health and prevent fractures.” Dr. Famida Jiwa, President and CEO, Osteoporosis Canada added, “Tens of thousands of Canadians suffer preventable fractures every year because their osteoporosis was undiagnosed and untreated, and this guideline is intended to help close the care gap.”

This new guideline builds on the foundation of the 2010 clinical guidelines, offering important updates to improve overall care delivery and treatment of osteoporosis.

In the coming weeks and months, Canadians will see new information, tools and resources released on the Osteoporosis Canada website.

Access the CMAJ link to view the guideline here.

INFORMATION:

Tracie Napoli
Director, Fund Development & MARCOM Osteoporosis Canada
tnapoli@osteoporosis.ca
416-696-2663 / 1-800-463-6842 ext. 2286  

About Osteoporosis Canada

Osteoporosis Canada (OC) is the only national Canadian organization serving people who have, or are at risk for, osteoporosis. The organization works to educate, empower and support individuals and communities in bone health and in the risk-reduction and treatment of osteoporosis. Osteoporosis Canada provides medically accurate information to patients, healthcare providers and the public and was the world’s first organization dedicated to osteoporosis, the first to establish bone health recommendations for long-term care residents and exercise, and the first to introduce fracture risk assessment. The Scientific Advisory Council (SAC) is made up of experts in osteoporosis and bone metabolism and is a volunteer membership. Comprised of clinicians, researchers and educators, the SAC advises Osteoporosis Canada’s board and staff on scientific and medical issues.

LEARN MORE

LATEST NEWS


OC MAKES THE NEWS- Recent ITEMS

Highlighted

Continue reading

© Osteoporosis Canada, 2025
Charitable Registration No. 89551 0931 RR 0001